# Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

> **NCT04124926** · PHASE3 · COMPLETED · sponsor: **Phathom Pharmaceuticals, Inc.** · enrollment: 1027 (actual)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT04124926
- **Lead sponsor:** Phathom Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-28
- **Primary completion:** 2021-07-29
- **Final completion:** 2021-08-24
- **Target enrollment:** 1027 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04124926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04124926, "Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04124926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*